Showing 4581-4590 of 6036 results for "".
- Pixium Vision Reaches Enrollment Target in the European Pivotal Trial PRIMAverahttps://modernod.com/news/pixium-vision-reaches-enrollment-target-in-the-european-pivotal-trial-primavera/2481101/Pixium Vision SA announced the completion of patient enrollment in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration (AMD), also known as geographic atrophy. A total of 38 patients have been enrolled in the PRIMAvera study
- Shamir Glacier PLUS Metaform on 1.6 and 1.67 Now Availablehttps://modernod.com/news/shamir-glacier-plus-metaform-on-16-and-167-now-available/2481093/Shamir announced the availability of the new Glacier PLUS Metaform lens-coating technology, which uses fewer resources and chemicals in its production than its premium AR coating, making it an eco-friendly option for consumers. According to Shamir, features of the new len
- Glaukos Announces Positive Topline Outcomes in Two Phase 3 Pivotal Trials of iDose TRhttps://modernod.com/news/glaukos-announces-positive-topline-outcomes-for-both-phase-3-pivotal-trials-of-idose-tr/2481092/Glaukos announced positive topline data for both phase 3 pivotal trials of iDose TR that successfully achieved its prespecified primary efficacy endpoints through 3 months in both phase 3 trials and demonstrated excellent tolerability and a favorable safety profile through 1
- Bausch + Lomb Sponsored Visionary Report Spotlights Nation's 'Blind Spots' on AMDhttps://modernod.com/news/bausch-lomb-sponsored-visionary-report-spotlights-nations-blind-spots-on-amd/2481091/Bausch + Lomb released a report of survey results from the company’s first Visionary Report, which was designed to identify new key insights into the value Americans place on their eyesight, as well as the ‘blind spots’ that may exist in the understanding and aware
- Sight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare System vs Restasishttps://modernod.com/news/sight-sciences-announces-completion-of-enrollment-in-sahara-a-randomized-clinical-trial-of-the-tearcare-system-vs-restasis/2481086/Sight Sciences announced the completion of enrollment in the SAHARA trial, a study designed to evaluate whether an interventional dry eye procedure with the TearCare System is superior in alleviating the signs and symptoms of dry eye disease compared to 6-months of twice daily Restasis&
- Ciliatech Presents New Concept in Glaucoma Implants, First to Bypass Opening Anterior Eye Chamberhttps://modernod.com/news/ciliatech-presents-new-concept-in-glaucoma-implants-first-to-bypass-opening-anterior-eye-chamber/2481085/Ciliatech, which is developing a new class of implant to treat glaucoma durably named
- Pixium Vision Announces Implantation of First Patient in Italy in Prima System European Pivotal Trial PRIMAverahttps://modernod.com/news/pixium-vision-announces-implantation-of-first-patient-in-italy-in-prima-system-european-pivotal-trial-primavera/2481084/Pixium Vision announced the successful first implantation of a patient in Italy in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration (dry AMD). This follows the approval of the PRIMAvera study by the Italian Ministry of Health and the opening of the first clinical
- Trukera Medical Launches ScoutPro Osmolarity Systemhttps://modernod.com/news/trukera-medical-launches-new-scoutpro-osmolarity-system/2481081/Trukera Medical unveiled the first product under the new company name, the ScoutPro Osmolarity System. Designed to help advance corneal health decisions for busy eye care practices, ScoutPro is the first and only portable osmometer in the United States. The launch comes a wee
- Cellusion and Celregen Enter into License Agreement of CLS001 for a Corneal Endothelial Cell Regenerative Therapy in the Greater Chinahttps://modernod.com/news/cellusion-and-celregen-enter-into-license-agreement-of-cls001-for-a-corneal-endothelial-cell-regenerative-therapy-in-the-greater-china/2481079/Cellusion, a Japanese regenerative medicine startup, and Hangzhou Celregen Therapeutics, a member of Shanghai Fosun Pharmaceutical, announced an exclusive license agreement in the Greater China region for Celregen to develop, manufacture and commercialize CLS001. Under the agr
- ESCRS Launches New Awards Program to Foster Digital Transformationhttps://modernod.com/news/escrs-launches-new-awards-program-to-foster-digital-transformation/2481078/The European Society of Cataract & Refractive Surgeons (ESCRS) announced the launch of the 2022 ESCRS Digital Research Awards (DRA), an initiative sponsored by the society to support and encourage innovative research that leads to digital transformation in the fields of cataract, re
